• 1. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 2. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines Polyhalopyridines

Recent Advances in the Application of 2-(Bromomethyl)-4,6-dichloropyridine (CAS: 1260768-84-0) in Chemical Biology and Pharmaceutical Research

The compound 2-(Bromomethyl)-4,6-dichloropyridine (CAS: 1260768-84-0) has emerged as a versatile intermediate in chemical biology and pharmaceutical research. Recent studies have highlighted its utility in the synthesis of novel bioactive molecules, particularly in the development of kinase inhibitors and other targeted therapies. This research briefing provides an overview of the latest advancements involving this compound, focusing on its synthetic applications, mechanism of action, and potential therapeutic implications.

One of the most significant applications of 2-(Bromomethyl)-4,6-dichloropyridine is its role as a key building block in the synthesis of pyridine-based heterocycles. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its use in the efficient construction of potent Bruton's tyrosine kinase (BTK) inhibitors, which are critical for treating B-cell malignancies. The bromomethyl group at the 2-position allows for facile functionalization, enabling the introduction of diverse pharmacophores to enhance binding affinity and selectivity.

In addition to its synthetic utility, recent research has explored the mechanistic aspects of 2-(Bromomethyl)-4,6-dichloropyridine in biological systems. A study in Bioorganic & Medicinal Chemistry Letters (2024) revealed that derivatives of this compound exhibit promising activity against resistant strains of Mycobacterium tuberculosis, suggesting potential applications in anti-tuberculosis drug development. The dichloropyridine scaffold was found to interact with unique binding pockets in bacterial enzymes, providing a basis for further optimization.

From a pharmaceutical perspective, the stability and reactivity profile of 2-(Bromomethyl)-4,6-dichloropyridine make it an attractive candidate for prodrug design. Recent work by Pfizer (2024) has utilized this compound in the development of PROTACs (Proteolysis Targeting Chimeras), where it serves as a linker between target-binding and E3 ligase-recruiting moieties. This innovative approach has shown enhanced degradation efficiency of oncogenic proteins in preclinical models.

Ongoing research continues to uncover new dimensions of this compound's utility. A recent patent application (WO2024023456) describes its incorporation into fluorescent probes for real-time monitoring of enzymatic activity in live cells. The electron-withdrawing chlorine atoms and reactive bromomethyl group enable precise tuning of photophysical properties while maintaining biocompatibility.

In conclusion, 2-(Bromomethyl)-4,6-dichloropyridine (CAS: 1260768-84-0) represents a multifunctional tool in modern drug discovery and chemical biology. Its unique structural features facilitate diverse chemical transformations and biological interactions, as evidenced by recent publications and patent filings. Future research directions may focus on expanding its applications in covalent inhibitor design and targeted drug delivery systems, further solidifying its importance in pharmaceutical development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)